Description du projet
Vers de nouveaux produits biopharmaceutiques ciblant le système nerveux central
Des millions de citoyens européens sont atteints de troubles du système nerveux central (SNC), comme la sclérose en plaques, la maladie d’Alzheimer et la maladie de Parkinson. Actuellement, les médicaments ayant une faible biodisponibilité au niveau du SNC sont administrés directement au SNC par le biais d’injections intrathécales, intracérébroventriculaires ou intraparenchymateuses qui, toutefois, nécessitent une intervention chirurgicale. Pour répondre à cette contrainte, le projet Bio2Brain, financé par l’UE, formera des chercheurs en début de carrière au développement de technologies innovantes pour administrer des produits biopharmaceutiques de manière sûre par voie nasale. Les résultats du projet devraient aborder la faible disponibilité des médicaments ciblant le SNC, notamment des produits biopharmaceutiques comme les anticorps monoclonaux, qui reste un défi de taille dans le traitement des troubles du SNC.
Objectif
Bio2Brain aims to create a trans-European network of industrially oriented specialists fully trained and experienced, a significant driving force in innovating novel technologies to deliver biopharmaceuticals safely and via the nasal route of administration to the central nervous system (CNS). Diseases of the CNS and the spinal cord affect around 165 million Europeans with disorders such as Multiple Sclerosis, Alzheimer’s disease and Parkinson’s disease. CNS disorders are often connected with high morbidity, significant side effects, suffering of the patients and their families, as well as an enormous burden on the welfare systems. Therefore, in terms of social sustainability, Bio2Brain contributes to increased benefit for both, the society as whole and particularly for those individuals at a disadvantage through these disorders. A highly critical challenge of CNS diseases is the low central availability drugs in general and in particular of biopharmaceuticals like monoclonal antibodies (mAbs). Hence, approved medicinal products with a low CNS bioavailability are currently delivered via intrathecal, intracerebroventricular or intraparenchymal injections. In this way, they are delivered directly to the CNS. Unfortunately, such delivery systems are invasive, require a surgery with high risks, have a low patient compliance and are poorly controllable. Therefore, there is a critical need for a more safe and effective new approach, that means a paradigm shift, for drug delivery technologies in the treatment of CNS diseases. The Bio2Brain network will create a research environment for the interdisciplinary and intersectorial training of 13 ESRs supported by 11 academic teams (beneficiaries and partner universities), 6 key industrial stakeholders and an academic non-profit organization. As an important benefit, the close and frequent exposure of the ESRs to the private sector and to key technologies will significantly enhance their employability.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
80686 Munchen
Allemagne